Patents by Inventor Daqing Sun

Daqing Sun has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • OLED display panel and OLED display device
    Patent number: 12250863
    Abstract: Provided is an OLED display panel, the OLED display panel includes a touch layer, wherein the touch layer includes a via hole structure including: a first conductive layer, an interlayer insulating layer, and a second conductive layer that are sequentially arranged, wherein the interlayer insulating layer is provided with a via hole, the second conductive layer is overlapped with the first conductive layer by the via hole, and at least part of a surface, in contact with the second conductive layer, of the interlayer insulating layer is uneven; wherein the uneven surface has a roughness in a value range of 0.05d?r?0.19d, where r represents the roughness, and d represents a thickness of the interlayer insulating layer, the roughness of the uneven surface being a distance between a top of convex and a bottom of concave in the uneven surface.
    Type: Grant
    Filed: April 26, 2022
    Date of Patent: March 11, 2025
    Assignees: MIANYANG BOE OPTOELECTRONICS TECHNOLOGY CO., LTD, BOE TECHNOLOGY GROUP CO., LTD.
    Inventors: Lei Zhang, Daqing Sun, Wei Qiu, Fangliang Yan
  • 3CLPRO PROTEASE INHIBITOR
    Publication number: 20250042889
    Abstract: Provided are a 3Clpro protease inhibitor, a pharmaceutical composition containing the compound of formula (I), and a method for treating coronavirus by using the compound.
    Type: Application
    Filed: September 6, 2022
    Publication date: February 6, 2025
    Applicants: SHANGHAI QILU PHARMACEUTICAL RESEARCH AND DEVELOPMENT CENTRE LTD., QILU ANIMAL HEALTH PRODUCTS CO., LTD.
    Inventors: Junfei WANG, Cang CHENG, Bo CHI, Daqing SUN
  • CD73 INHIBITORS
    Publication number: 20250034198
    Abstract: Described herein are CD73 inhibitors and pharmaceutical compositions comprising said compounds. The subject compounds and compositions are useful for the treatment of cancer, infections, and neurodegenerative diseases.
    Type: Application
    Filed: May 10, 2024
    Publication date: January 30, 2025
    Inventors: Xiaohui DU, John EKSTEROWICZ, Valeria R. FANTIN, Daqing SUN, Qiuping YE, Jared MOORE, Tatiana ZAVOROTINSKAYA, Brian R. BLANK, Yosup REW, Kejia WU, Liusheng ZHU, Johnny PHAM, Hiroyuki KAWAI, Chien-Hung YEH
  • CDK INHIBITOR
    Publication number: 20250009745
    Abstract: A compound serving as a selective CDK inhibitor, a pharmaceutical composition containing same, a useful intermediate for preparing the compound, and a use of the compound for preparing a drug for the treatment of cell proliferative diseases, such as cancer. The compound has the structure shown in formula (I-A).
    Type: Application
    Filed: January 28, 2022
    Publication date: January 9, 2025
    Inventors: Xiaoxia YAN, Daqing SUN
  • NOVEL PARP7 INHIBITOR AND USE THEREOF
    Publication number: 20240351997
    Abstract: Disclosed are a compound serving as a PARP7 inhibitor, and a use thereof in preparing a drug for treating relevant diseases. Specifically disclosed are a compound represented by formula (I) and a pharmaceutically acceptable salt thereof. The compound can be used for treating cancer.
    Type: Application
    Filed: July 28, 2022
    Publication date: October 24, 2024
    Inventors: Xiaoxia YAN, Guanxin HUANG, Wei JU, Daqing SUN
  • Piperidinone Derivatives as MDM2 Inhibitors for the Treatment of Cancer
    Publication number: 20240300892
    Abstract: The present invention provides MDM2 inhibitor compounds of Formula I, wherein the variables are defined above, which compounds are useful as therapeutic agents, particularly for the treatment of cancers. The present invention also relates to pharmaceutical compositions that contain an MDM2 inhibitor.
    Type: Application
    Filed: October 11, 2023
    Publication date: September 12, 2024
    Inventors: Michael D. Bartberger, Ana Gonzalez Buenrostro, Hilary Plake Beck, Xiaoqi Chen, Richard Victor Connors, Jeffrey Deignan, Jason A. Duquette, I, John Eksterowicz, Benjamin Fisher, Brian M. Fox, Jiasheng Fu, Zice Fu, Felix Gonzalez Lopez De Turiso, Michael W. Gribble, Darin J. Gustin, Julie A. Heath, Xin Huang, XianYun Jiao, Michael G. Johnson, Frank Kayser, David John Kopecky, SuJen Lai, Yihong Li, Zhihong Li, Jiwen Liu, Jonathan D. Low, Brian S. Lucas, Zhihua MA, Lawrence R. McGee, Joel McIntosh, Dustin L. McMinn, Julio C. Medina, Jeffrey Thomas Mihalic, Steven H. Olson, Yossup Rew, Philip M. Roveto, Daqing Sun, Xiaodong Wang, Yingcai Wang, Xuelei Yan, Ming Yu, Jiang Zhu
  • CD73 inhibitors
    Patent number: 12018043
    Abstract: Described herein are CD73 inhibitors and pharmaceutical compositions comprising said compounds. The subject compounds and compositions are useful for the treatment of cancer, infections, and neurodegenerative diseases.
    Type: Grant
    Filed: October 31, 2022
    Date of Patent: June 25, 2024
    Assignee: ORIC PHARMACEUTICALS, INC.
    Inventors: Xiaohui Du, John Eksterowicz, Valeria R. Fantin, Daqing Sun, Qiuping Ye, Jared Moore, Tatiana Zavorotinskaya, Brian R. Blank, Yosup Rew, Kejia Wu, Liusheng Zhu, Johnny Pham, Hiroyuki Kawai, Chien-Hung Yeh
  • CD73 INHIBITORS
    Publication number: 20240124512
    Abstract: Described herein are CD73 inhibitors and pharmaceutical compositions comprising said compounds. The subject compounds and compositions are useful for the treatment of cancer, infections, and neurodegenerative diseases.
    Type: Application
    Filed: September 28, 2023
    Publication date: April 18, 2024
    Inventors: Xiaohui DU, John EKSTEROWICZ, Valeria R. FANTIN, Daqing SUN, Qiuping YE, Jared MOORE, Tatiana ZAVOROTINSKAYA, Brian R. BLANK, Yosup REW, Kejia WU, Liusheng ZHU, Johnny PHAM, Hiroyuki KAWAI
  • CD73 inhibitors
    Patent number: 11807658
    Abstract: Described herein are CD73 inhibitors and pharmaceutical compositions comprising said compounds. The subject compounds and compositions are useful for the treatment of cancer, infections, and neurodegenerative diseases.
    Type: Grant
    Filed: March 17, 2022
    Date of Patent: November 7, 2023
    Assignee: ORIC PHARMACEUTICALS, INC.
    Inventors: Xiaohui Du, John Eksterowicz, Valeria R. Fantin, Daqing Sun, Qiuping Ye, Jared Moore, Tatiana Zavorotinskaya, Brian R. Blank, Yosup Rew, Kejia Wu, Liusheng Zhu, Johnny Pham, Hiroyuki Kawai
  • CD73 INHIBITORS
    Publication number: 20230131747
    Abstract: Described herein are CD73 inhibitors and pharmaceutical compositions comprising said compounds. The subject compounds and compositions are useful for the treatment of cancer, infections, and neurodegenerative diseases.
    Type: Application
    Filed: October 31, 2022
    Publication date: April 27, 2023
    Inventors: Xiaohui DU, John EKSTEROWICZ, Valeria R. FANTIN, Daqing SUN, Qiuping YE, Jared MOORE, Tatiana ZAVOROTINSKAYA, Brian R. BLANK, Yosup REW, Kejia WU, Liusheng ZHU, Johnny PHAM, Hiroyuki KAWAI, Chien-Hung YEH
  • INHIBITORS OF GLUCOCORTICOID RECEPTOR
    Publication number: 20230096870
    Abstract: The present invention relates generally to compositions and methods for treating cancer and hypercortisolism. Provided herein are substituted steroidal derivative compounds and pharmaceutical compositions comprising said compounds. The subject compounds and compositions are useful for inhibition of glucocorticoid receptors. Furthermore, the subject compounds and compositions are useful for the treatment of cancer.
    Type: Application
    Filed: August 15, 2022
    Publication date: March 30, 2023
    Inventors: Daqing SUN, Lawrence R. McGEE, Xiaohui DU, Liusheng ZHU, Xuelei YAN, Yosup REW, John EKSTEROWICZ, Julio C. MEDINA, Valeria R. FANTIN, Haiying ZHOU, Minna Delarae BALBAS
  • CD73 inhibitors
    Patent number: 11576922
    Abstract: Described herein are CD73 inhibitors and pharmaceutical compositions comprising said compounds. The subject compounds and compositions are useful for the treatment of cancer, infections, and neurodegenerative diseases.
    Type: Grant
    Filed: August 17, 2021
    Date of Patent: February 14, 2023
    Assignee: ORIC PHARMACEUTICALS, INC.
    Inventors: Xiaohui Du, John Eksterowicz, Valeria R. Fantin, Erica L. Jackson, Daqing Sun, Qiuping Ye, Jared Moore
  • CD73 INHIBITORS
    Publication number: 20220411459
    Abstract: Described herein are CD73 inhibitors and pharmaceutical compositions comprising said compounds. The subject compounds and compositions are useful for the treatment of cancer, infections, and neurodegenerative diseases.
    Type: Application
    Filed: October 29, 2020
    Publication date: December 29, 2022
    Inventors: Xiaohui DU, John EKSTEROWICZ, Valeria R. FANTIN, Daqing SUN, Qiuping YE, Jared MOORE, Tatiana ZAVOROTINSKAYA, Brian R. BLANK, Yosup REW, Kejia WU, Liusheng ZHU, Johnny PHAM, Hiroyuki KAWAI, Chien-Hung YEH
  • CD73 inhibitors
    Patent number: 11530236
    Abstract: Described herein are CD73 inhibitors and pharmaceutical compositions comprising said compounds. The subject compounds and compositions are useful for the treatment of cancer, infections, and neurodegenerative diseases.
    Type: Grant
    Filed: October 29, 2020
    Date of Patent: December 20, 2022
    Assignee: ORIC PHARMACEUTICALS, INC.
    Inventors: Xiaohui Du, John Eksterowicz, Valeria R. Fantin, Daqing Sun, Qiuping Ye, Jared Moore, Tatiana Zavorotinskaya, Brian R. Blank, Yosup Rew, Kejia Wu, Liusheng Zhu, Johnny Pham, Hiroyuki Kawai, Chien-Hung Yeh
  • CD73 INHIBITORS
    Publication number: 20220331343
    Abstract: Described herein are CD73 inhibitors and pharmaceutical compositions comprising said compounds. The subject compounds and compositions are useful for the treatment of cancer, infections, and neurodegenerative diseases.
    Type: Application
    Filed: July 15, 2020
    Publication date: October 20, 2022
    Inventors: Xiaohui DU, John EKSTEROWICZ, Valeria R. FANTIN, Daqing SUN, Qiuping YE, Jared MOORE, Tatiana ZAVOROTINSKAYA, Brian R. BLANK, Hiroyuki KAWAI, Chien-Hung YEH, Yosup REW, Kejia WU, Johnny PHAM
  • CD73 INHIBITORS
    Publication number: 20220259253
    Abstract: Described herein are CD73 inhibitors and pharmaceutical compositions comprising said compounds. The subject compounds and compositions are useful for the treatment of cancer, infections, and neurodegenerative diseases.
    Type: Application
    Filed: April 18, 2022
    Publication date: August 18, 2022
    Inventors: Xiaohui DU, John EKSTEROWICZ, Valeria R. FANTIN, Erica L. JACKSON, Daqing SUN, Qiuping YE, Jared MOORE, Tatiana ZAVOROTINSKAYA
  • OLED DISPLAY PANEL AND OLED DISPLAY DEVICE
    Publication number: 20220254838
    Abstract: Provided is an OLED display panel, the OLED display panel includes a touch layer, wherein the touch layer includes a via hole structure including: a first conductive layer, an interlayer insulating layer, and a second conductive layer that are sequentially arranged, wherein the interlayer insulating layer is provided with a via hole, the second conductive layer is overlapped with the first conductive layer by the via hole, and at least part of a surface, in contact with the second conductive layer, of the interlayer insulating layer is uneven; wherein the uneven surface has a roughness in a value range of 0.05d?r?0.19d, where r represents the roughness, and d represents a thickness of the interlayer insulating layer, the roughness of the uneven surface being a distance between a top of convex and a bottom of concave in the uneven surface.
    Type: Application
    Filed: April 26, 2022
    Publication date: August 11, 2022
    Inventors: Lei Zhang, Daqing Sun, Wei Qiu, Fangliang Yan
  • CIS-morpholinone and other compounds as MDM2 inhibitors for the treatment of cancer
    Patent number: 11407721
    Abstract: The present invention provides MDM2 inhibitor compounds of Formula I, or the pharmaceutically acceptable salts thereof, wherein the variables are defined above, which compounds are useful as therapeutic agents, particularly for the treatment of cancers. The present invention also relates to pharmaceutical compositions that contain an MDM2 inhibitor.
    Type: Grant
    Filed: July 30, 2018
    Date of Patent: August 9, 2022
    Assignee: AMGEN INC.
    Inventors: Michael D. Bartberger, Hilary Plake Beck, Michael R. Degraffenreid, Brian M. Fox, Felix Gonzalez Lopez De Turiso, Lisa D. Julian, Frank Kayser, Julio C. Medina, Steven H. Olson, Yosup Rew, Philip M. Roveto, Daqing Sun, Xuelei Yan
  • CD73 INHIBITORS
    Publication number: 20220220147
    Abstract: Described herein are CD73 inhibitors and pharmaceutical compositions comprising said compounds. The subject compounds and compositions are useful for the treatment of cancer, infections, and neurodegenerative diseases.
    Type: Application
    Filed: March 17, 2022
    Publication date: July 14, 2022
    Inventors: Xiaohui DU, John EKSTEROWICZ, Valeria R. FANTIN, Daqing SUN, Qiuping YE, Jared MOORE, Tatiana ZAVOROTINSKAYA, Brian R. BLANK, Yosup REW, Kejia WU, Liusheng ZHU, Johnny PHAM, Hiroyuki KAWAI
  • CD73 inhibitors
    Patent number: 11377469
    Abstract: Described herein are CD73 inhibitors and pharmaceutical compositions comprising said compounds. The subject compounds and compositions are useful for the treatment of cancer, infections, and neurodegenerative diseases.
    Type: Grant
    Filed: November 2, 2018
    Date of Patent: July 5, 2022
    Assignee: ORIC PHARMACEUTICALS, INC.
    Inventors: Xiaohui Du, John Eksterowicz, Valeria R. Fantin, Erica L. Jackson, Daqing Sun, Qiuping Ye, Jared Moore, Tatiana Zavorotinskaya